Mitsubishi Tanabe Drug Patent Portfolio
Mitsubishi Tanabe owns 2 orange book drugs protected by 6 US patents Given below is the list of Mitsubishi Tanabe's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10987341 | Edaravone suspension for oral administration | 01 Nov, 2039 | Active |
| US11241416 | Edaravone suspension for oral administration | 01 Nov, 2039 | Active |
| US11478450 | Edaravone suspension for oral administration | 01 Nov, 2039 | Active |
| US11826352 | Edaravone suspension for oral administration | 01 Nov, 2039 | Active |
| US11957660 | Edaravone suspension for oral administration | 01 Nov, 2039 | Active |
| US6933310 | Therapeutic agent for amyotrophic lateral sclerosis (ALS) | 13 Nov, 2020 | Expired |
Latest Legal Activities on Mitsubishi Tanabe's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Mitsubishi Tanabe.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Recordation of Patent Grant Mailed
Critical
| 16 Apr, 2024 | US11957660 |
| Mail Patent eGrant Notification | 16 Apr, 2024 | US11957660 |
| Recordation of Patent eGrant | 16 Apr, 2024 | US11957660 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 16 Apr, 2024 | US11957660 |
|
Email Notification
Critical
| 16 Apr, 2024 | US11957660 |
| Patent eGrant Notification | 16 Apr, 2024 | US11957660 |
|
Email Notification
Critical
| 28 Mar, 2024 | US11957660 |
|
Issue Notification Mailed
Critical
| 27 Mar, 2024 | US11957660 |
| Dispatch to FDC | 21 Mar, 2024 | US11957660 |
|
Application Is Considered Ready for Issue
Critical
| 21 Mar, 2024 | US11957660 |
|
Issue Fee Payment Received
Critical
| 20 Mar, 2024 | US11957660 |
|
Issue Fee Payment Verified
Critical
| 20 Mar, 2024 | US11957660 |
|
Electronic Review
Critical
| 20 Dec, 2023 | US11957660 |
|
Email Notification
Critical
| 20 Dec, 2023 | US11957660 |
|
Mail Notice of Allowance
Critical
| 20 Dec, 2023 | US11957660 |
Mitsubishi Tanabe's Family Patents
Mitsubishi Tanabe Drug List
Given below is the complete list of Mitsubishi Tanabe's drugs and the patents protecting them.
1. Radicava
Radicava is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6933310 | Therapeutic agent for amyotrophic lateral sclerosis (ALS) |
13 Nov, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Radicava's drug page
2. Radicava Ors
Radicava Ors is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10987341 | Edaravone suspension for oral administration |
01 Nov, 2039
(14 years from now)
| Active |
| US11241416 | Edaravone suspension for oral administration |
01 Nov, 2039
(14 years from now)
| Active |
| US11478450 | Edaravone suspension for oral administration |
01 Nov, 2039
(14 years from now)
| Active |
| US11826352 | Edaravone suspension for oral administration |
01 Nov, 2039
(14 years from now)
| Active |
| US11957660 | Edaravone suspension for oral administration |
01 Nov, 2039
(14 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Radicava Ors's drug page